Astrazeneca Ab

Astazeneca Ab

Heather Marie Redfearn

Maurice Raymond Verschoyle Finlay

Richard Andrew Ward

Sam Butterworth

Robert Hugh Bradbury

Alfred Arthur Rabow

David Buttar

Christopher De Savi

Craig Samuel Donald

Gordon Stuart Currie

Richard Albert Norman

Nadim Akhtar

Helen Elizabeth Williams

Matthew Osborne

Neda Yavari

Claudio Edmundo Chuaqui

Andiappan Murugan

Chandrasekhara Reddy Chintakuntla

Vasantha Krishna Kadambar

Maurice Raymond Finlay

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

2-(2,4,5-substituted-anilino)pyrimidine compounds

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Chemical compounds

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising such compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of such compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.

2-(2,4,5-substituted-anilino) pyrimidine compounds

Growing community of inventors

Macclesfield, United Kingdom

Heather Marie Redfearn